As per Data Bridge Market Research analysis, the bendamustine market was valued at USD 786.00 million in 2025 and is projected to reach USD 1,188.09 million by 2033, growing at a CAGR of 5.30% from 2026 to 2033.
The market is experiencing consistent growth driven by the rising prevalence of hematological malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), increasing demand for effective chemotherapy treatments, and expanding use of bendamustine-based combination therapies.
1 View